AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn’s Disease
CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2 Crohn’s disease is a chronic, systemic disease that manifests as inflammation… Read More




